Delta sleep-inducing peptide showed weak objective sleep improvements but no subjective benefit in chronic insomniacs, leading researchers to conclude it's unlikely to be a useful insomnia treatment.
Weak effects onlyDSIP improved some objective sleep measures versus placebo, but effects were weak, possibly confounded, and patients didn't feel better
What the researchers found
In this double-blind trial, delta sleep-inducing peptide (DSIP) showed some objective sleep improvements in chronic insomniacs — higher sleep efficiency and shorter time to fall asleep compared to placebo. One subjective tiredness measure also improved.
However, the researchers concluded these effects were weak and potentially confounded by changes in the placebo group. Other measures including subjective sleep quality showed no improvement. The authors' overall conclusion was negative: short-term DSIP treatment is unlikely to provide major therapeutic benefit for chronic insomnia.
Why it matters
DSIP was one of the earliest peptides investigated as a potential sleep aid, generating significant excitement when it was first identified in the 1970s. This was one of the few properly controlled human trials testing whether DSIP actually improves sleep. The largely negative result was important for the field — it tempered expectations about DSIP as a therapeutic peptide and highlighted the gap between a peptide's name/theoretical function and its actual clinical utility.
The numbers in context
n=16 patients · Double-blind, parallel groups · 25 nmol/kg body weight DSIP IV · 3 treatment nights · Higher sleep efficiency and shorter sleep latency vs. placebo (but weak effects) · No subjective sleep quality improvement
How the study worked
Double-blind, matched-pairs, parallel-groups design. 16 chronic insomnia patients spent 5 consecutive nights in a sleep lab. Night 1 was adaptation, night 2 was baseline. Before nights 3-5, half received IV DSIP (25 nmol/kg) and half received glucose placebo. Polysomnography measured objective sleep architecture, and subjective sleep quality and tiredness were also assessed.
Who was studied
16 chronic insomnia patients (adults, mixed ages), double-blind parallel groups
What this study cannot tell us
Very small sample size (n=16, only 8 per group). Only 3 treatment nights — too short to assess sustained effects. IV administration is impractical for real-world insomnia treatment. The statistically significant findings were weak and potentially driven by placebo group changes rather than true DSIP effects. Published in 1992 with older statistical methods.
How to read the evidence
Moderate evidence — a properly designed double-blind, placebo-controlled trial, but severely limited by the tiny sample size (n=16) and short treatment duration (3 nights). The largely negative results are informative despite the small study.
When this study was published
Published in 1992. This is a historical study from the early era of sleep peptide research. DSIP has not since demonstrated robust clinical efficacy for insomnia in any larger trials.
The bigger picture
DSIP represented an early hope that peptide neuroscience could yield better sleep drugs. This negative result is part of a pattern — many neuropeptides that showed promise in animal models failed to deliver robust effects in human clinical settings. Despite this, sleep-related peptide research has continued and evolved, with the discovery of the orexin/hypocretin system eventually leading to successful insomnia drugs (suvorexant, lemborexant) that target neuropeptide receptors.
Questions still open
- Would longer DSIP treatment periods or different dosing routes produce more meaningful effects?
- Does DSIP play a real physiological role in sleep regulation, or was the original naming misleading?
- Could DSIP-based approaches work for specific insomnia subtypes rather than chronic insomnia broadly?
Common questions
Does DSIP actually help you sleep?
Why is DSIP still sold as a supplement if it doesn't work?
Read the original research
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.
Neuropsychobiology, 26(4), 193-7
Citation
Bes, F; Hofman, W; Schuur, J; Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.. Neuropsychobiology, 26(4), 193-7.